Search
for
Sort by
Research 631–660 of 1000+
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Pericardial Disorders Occurring during Open Label Study of 3747 Patients Treated with Systemic Minoxidil
- Combination of oral minoxidil and bicalutamide for the treatment of female pattern hair loss in adolescents
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- Sublingual Minoxidil Increases Fibre Diameter in Male Androgenetic Alopecia. - A proxy for Reversal of Hair Follicle Miniaturization.
- Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double‐blind randomized clinical trial
- Clinical Safety and Efficacy of Dual Wavelength Low-Level Light Therapy in Androgenetic Alopecia: A Double-Blind Randomized Controlled Study
- Australian dermatologists' prescribing behaviours for female androgenetic alopecia
- Painful bilateral gynaecomastia secondary to topical finasteride
- Hair presentation test
- Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss
- Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
- BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
- Dissecting cellulitis of the scalp in a paediatric male
- Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
- Novel investigational drugs for alopecia areata and future perspectives
- Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
- Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data
- Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response